The Tirzepatide Telehealth Market

Who left during 2026

Five of the largest names on this site no longer sell compounded tirzepatide. Ro and the WeightWatchers clinic carry brand-name products with membership billed separately. Hims closed its compounded programme to new patients after a March 2026 settlement. Calibrate operates a brand-only membership model. Noom's published figures describe brand Zepbound.

That matters for anyone reading an older comparison. A list ranking those companies for compounded tirzepatide is describing a product they do not sell, and the verification date is the only way to tell. It also means the cheap end of this market is now served by smaller operators with far less brand recognition, which raises the value of verifying the pharmacy rather than trusting the name.

The shape of the market

We track 32 tirzepatide telehealth programmes. 17 publish a price we could capture. All-in cost at a 10 mg dose runs from $129 to $399 a month for compounded tirzepatide from the same category of licensed pharmacy.

That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing and margin.

Two pricing models, one of them dominant

10 of the 15 programs we can price hold one price at every strength; the rest reprice as the dose climbs or print one price only. The second group's advertised figure describes roughly four weeks of a twelve-month course.

Fee structures fragment the comparison

6 programmes charge a mandatory recurring fee on top of medication. Comparisons quoting medication alone understate those programmes by the full membership, permanently.

Disclosure is the exception

Only 4 of the 15 programs we can price at 10 mg name their dispensing pharmacies before purchase. That single disclosure is the one that lets a patient check a state board register, and it costs a programme nothing to publish.

What we could not establish

Shipping reliability, response times, clinical quality, or how any programme behaves when something goes wrong. None of it is measurable from outside, so none of it is in our tables.

Why this distinction changes what you pay

Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the lowest and highest all-in prices we track.

None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.

How to act on it this week

Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.

Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.

How this connects to what you will actually pay

Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 15 programs we can price at 10 mg, that runs from $129 to $399 a month all-in, about three times as much at the top as at the bottom, for compounded tirzepatide from the same category of licensed pharmacy.

One of those 15 programs charges a recurring program fee on top of medication, and 10 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.

What we could verify and what we could not

15 of the 32 programs we track have a month-to-month 10 mg price we read on the program’s own site (October 15, 2026; NexLife as of November 6, 2026). The rest print no comparable price, blocked our reader or sell brand Zepbound only, and we show no third-party figure for them. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.

Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.

The regulatory distinction that sits under all of this

Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. Compounded tirzepatide is made with the drug in Zepbound but is not the same product, and FDA does not review it before sale; the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.

That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.

Method

Computed over one file covering 32 programmes on a single price basis: all-in monthly cost, medication plus any recurring fee, at a named dose tier. No estimates, no imputed values, and no programme excluded for reasons other than the criterion stated.

Where a finding depends on a figure we could not verify at source, it is flagged rather than rounded away.

Findings

All-in cost at a 10 mg dose spans $129 to $399 a month, a threefold spread for compounded tirzepatide from the same category of licensed pharmacy. 10 of the 15 programs we can price hold one price at every dose; the rest reprice as you climb or print one price only. 6 charge a mandatory recurring fee on top of medication.

Few name the dispensing pharmacy before purchase, which is the single disclosure that would let a patient verify anything independently.

Limitations

Everything here comes from published material we could access. We did not enrol, did not mystery-shop, and did not contact programmes for comment before publication. Service quality, shipping reliability and clinical depth are absent because they are not measurable from outside.

A programme that discloses something we could not find should tell us, and the record will be corrected with the date.

Reuse

Cite freely with attribution and the capture date. Journalists and analysts should take the underlying file rather than transcribing from a table, because the file carries the evidence status that a table necessarily compresses.